On June 18, 2024, Bristol Myers Squibb announced the election of Michael R. McMullen as an independent director to its Board, effective July 1, 2024. McMullen, with over 20 years of executive experience, previously led Agilent Technologies as CEO, where he significantly increased market capitalization and improved profitability. His tenure at Agilent also included roles such as COO and President of the Chemical Analysis Group. McMullen, who holds an MBA from Wharton and a BS in finance and economics from the University of Delaware, is recognized for his leadership skills and successful track record in delivering shareholder returns. He currently serves on the board of KLA Corporation and is a senior advisor to Agilent. The Board has confirmed McMullen's independence according to NYSE standards, and he will join the Audit Committee. His compensation aligns with the company's standard for non-employee directors.

On June 18, 2024, Bristol Myers Squibb announced the election of Michael R. McMullen as an independent director to its Board, effective July 1, 2024. McMullen, with over 20 years of executive experience, previously led Agilent Technologies as CEO, where he significantly increased market capitalization and improved profitability. His tenure at Agilent also included roles such as COO and President of the Chemical Analysis Group. McMullen, who holds an MBA from Wharton and a BS in finance and economics from the University of Delaware, is recognized for his leadership skills and successful track record in delivering shareholder returns. He currently serves on the board of KLA Corporation and is a senior advisor to Agilent. The Board has confirmed McMullen's independence according to NYSE standards, and he will join the Audit Committee. His compensation aligns with the company's standard for non-employee directors.